Abstract
G protein-coupled receptor desensitization and trafficking are important regulators of opioid receptor signaling that can dictate overall drug responsiveness in vivo. Furthermore, different μ-opioid receptor (μOR) ligands can lead to varying degrees of receptor regulation, presumably because of distinct structural conformations conferred by agonist binding. For example, morphine binding produces a μOR with low affinity for β-arrestin proteins and limited receptor internalization, whereas enkephalin analogs promote robust trafficking of both β-arrestins and the receptors. Here, we evaluate μOR trafficking in response to activation by a novel μ-selective agonist derived from the naturally occurring plant product, salvinorin A. It is interesting that this compound, termed herkinorin, does not promote the recruitment of β-arrestin-2 to the μOR and does not lead to receptor internalization. Moreover, whereas G protein-coupled receptor kinase overexpression can promote morphine-induced β-arrestin interactions and μOR internalization, such manipulations do not promote herkinorin-induced trafficking. Studies in mice have shown that β-arrestin-2 plays an important role in the development of morphine-induced tolerance, constipation, and respiratory depression. Therefore, drugs that can activate the receptor without recruiting the arrestins may be a promising step in the development of opiate analgesics that distinguish between agonist activity and receptor regulation and may ultimately lead to therapeutics designed to provide pain relief without the adverse side effects normally associated with the opiate narcotics.
Footnotes
-
This work was supported by National Institute on Drug Abuse grants DA14600, DA18860 (to L.M.B), and DA18151 (to T.E.P).
-
Requests for compounds should be addressed to T.E.P. (thomasprisinzano{at}uiowa.edu).
-
ABBREVIATIONS: GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; βarr, β-arrestin; μOR, μ-opioid receptor; YFP, yellow fluorescent protein; GFP, green fluorescent protein; DAMGO, [d-Ala2,N-MePhe4,Gly-ol5]enkephalin; herkinorin, (2S,4aR,6aR,7R,9S, 10aS, 10bR)-9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho-[2,1-c]pyran-7-carboxylic acid methyl ester; DMSO, dimethyl sulfoxide; HEK, human embryonic kidney; PMSF, phenylmethylsulfonyl fluoride; PVDF, polyvinylidene difluoride; MAP, mitogen-activated protein; NP-40, Nonidet P-40; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; MEM, minimal essential medium; PKC, protein kinase C; ANOVA, analysis of variance; WT, wild type; HA, hemagglutinin; ERK1/2, extracellular signal-regulated kinases 1 and 2; MEF-WT, mouse embryonic fibroblasts expressing endogenous β-arrestins 1 and 2; MEF βarr1&2-KO, mouse embryonic fibroblasts lacking endogenous β-arrestins 1 and 2; DSP, dithiobis(succinimidylpropionate); U50,488H, (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide.
- Received June 22, 2006.
- Accepted November 6, 2006.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|